Reinvention of chemotherapy: drug conjugates and nanoparticlesNguyen-Ngoc, Tua; Raymond, Erica,bCurrent Opinion in Oncology: May 2015 - Volume 27 - Issue 3 - p 232–242 doi: 10.1097/CCO.0000000000000183 INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Recent advances in nanotechnology have addressed some of the issues related to lack of selectivity and nonspecific toxicities associated with conventional chemotherapy. Nanoparticles are therapeutic carriers that can be fine tuned for specific application and for passive or active tumor targeting. Recent findings Although the nanoparticle field is rapidly expanding, there are to date only six nanoparticle-based drug delivery platforms and two antibody–drug conjugates that are clinically approved for cancer therapy. Here, we review the clinical data of liposomal anthracyclines, nanoparticle formulations of paclitaxel and trastuzumab emtansine. We then briefly comment on efficacy and safety issues of nanoparticles, as well as on the next-generation nanoparticles for cancer therapy. Summary The emerging development of cancer nanotechnology offers the opportunity of reinvestigating the potential of cytotoxic agents, improving tumor targeting and drug delivery, leading to better safety profile and antitumor activity. Adding specificity to nanoparticles may allow personalization of cancer therapy using chemotherapy. aService d’oncologie médicale, Centre Hospitalier Universitaire Vaudois (CHUV) bFaculté de biologie et de médecine, Université de Lausanne (UNIL), Lausanne, Switzerland Correspondence to Eric Raymond, Service d’oncologie médicale, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland. Tel: +41 213143432; fax: +41 213140200; e-mail: firstname.lastname@example.org Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.